BerGenBio ASA: BerGenBio Reports Fourth Quarter 2022 Financi

BERGEN, Norway, Feb. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical

Related Keywords

Spain , Norway , Oslo , United Kingdom , Switzerland , Texas , United States , Norwegian , Dennis Riedl , Jan Lilleby , Martin Olin , John Heymach , Tony Mok , Graham Morrell , Enriqueta Felip , Prnewswire Bergenbio , Solange Peters , Investor Relations International Media , Hebron University Hospital , Md Anderson Cancer Center , Chinese University Of Hong Kong , Department Of Oncology At Lausanne University , Department Of Clinical Oncology , Clinical Development , Oslo Stock Exchange , Chief Executive Officer , Investigator Led Study , Respiratory Infections , Acute Respiratory Distress Syndrome , Thoracic Cancer Unit , Neck Medical Oncology , Cancer Center , Clinical Oncology , Chinese University , Hong Kong , Medical Oncology , Thoracic Malignancies , Lausanne University , Full Year Financial , Financial Reports , International Media Relations , Abuse Regulation , Norwegian Securities Trading , Bergenbio , Reports , Fourth , Quarter , 022 , Financial , Results , Rovides , Business , Update ,